Ratings ICON Public Limited Company

Equities

ICLR

IE0005711209

Real-time Estimate Cboe BZX Other stock markets 15:31:41 29/04/2024 BST			5-day change	1st Jan Change
306.9 ^USD	-0.47%		+3.06%	+8.47%

04-26	UBS Adjusts ICON Price Target to $380 From $368, Maintains Buy Rating	MT
04-25	Transcript : ICON Public Limited Company, Q1 2024 Earnings Call, Apr 25, 2024

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

With an expected P/E ratio at 31.31 and 25.79 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
With an enterprise value anticipated at 3.22 times the sales for the current fiscal year, the company turns out to be overvalued.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ICON PUBLIC LIMITED COMPANY	+8.47%	25.49B	B-
IQVIA HOLDINGS INC.	+2.41%	42.75B	B
LONZA GROUP AG	+47.87%	41.61B	A
MODERNA, INC.	+12.37%	41.34B	B-
CELLTRION, INC.	-12.36%	26.59B	C
ALNYLAM PHARMACEUTICALS, INC.	-23.67%	18.12B	B
MEDPACE HOLDINGS, INC.	+30.52%	12.24B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.56%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+8.09%	11B	B+
BIO-TECHNE CORPORATION	-14.83%	10.07B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes